Effectiveness and safety of tenofovir alafenamide/emtricitabine/bictegravir as a first-line regimen in people with HIV: A retrospective observational study
In our cohort of newly diagnosed PWH treated with TAF/FTC/BIC, the low occurrence of virological failure and discontinuation related to drug toxicities underscores the effectiveness and tolerability of the regimen.
Authors
- Davide Moschese (ORCID: https://orcid.org/0000-0001-5901-6742)
- Spinello Antinori (ORCID: https://orcid.org/0000-0003-0569-9407)
- Andrea Giacomelli (ORCID: https://orcid.org/0000-0003-3685-4289)
- Giacomo Pozza
- Serena Reato (ORCID: https://orcid.org/0000-0002-5867-509X)
- Martina Laura Colombo
- Anna Lisa Ridolfo (ORCID: https://orcid.org/0000-0003-1106-6219)
- Giorgia Carrozzo (ORCID: https://orcid.org/0009-0006-2752-9053)
- Maria Vittoria Cossu (ORCID: https://orcid.org/0000-0002-6984-3028)
- Federico Sabaini (ORCID: https://orcid.org/0009-0009-0334-0813)
- Cristina Gervasoni (ORCID: https://orcid.org/0000-0002-4922-6495)
- Chiara Fusetti (ORCID: https://orcid.org/0000-0002-1028-505X)
- Andrea Gori
Institutions
- University of Milan (IT)
- Luigi Sacco Hospital (IT)
- Centre for Multidisciplinary Research in Health Science (IT)
- ASST Fatebenefratelli Sacco (IT)
Publication Details
- Journal
- IJID Regions
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1016/j.ijregi.2025.100622
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences